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Intracellular Metbolism and Effects of
Circulating Cadmiu-Meallothionein in the
Kidney
by Katherine S. Squibb* and Bruce A. Fowlert
The mechanism ofcadmium-metallothionein (CdMT)-mediated nephrotoxicity is being
studied in rats using an acute dose regimen. Results of metabolism studies have shown
that injected CdMT is rapidly degraded by the kidney with the release of Cd2+ into the
cell cytoplasm. Ultrastructural studies indicate that an increase in the number of small
lysosomes is the first measurable effect ofCdMT in the kidney at 1 hr. This is followed by
anincrease inthe number ofsmall vesicles at4 hr. It is proposed that these effects are the
result of decreased primary lysosome formation and an inhibition of the fusion of
pinocytotic vesicles withcell lysosomes by Cd. Functional alterations measured 8 hr after
CdMT injection include an increase in urine volume and increased excretion of the low
molecular weight protein, RNAase. Prior induction of renal MT by Zn pretreatment
prevents the induction ofpolyuria andlow molecular weight proteinuria by CdMT. These
data provide further evidence that CdMT nephrotoxicity occurs as a result of Cd2+
toxicity within the cell.
The type of renal damage that is a primary
consequence of chronic cadmium exposure is
characterized by a low molecular weight pro-
teinuria that is indicative ofproximal tubule cell
dysfunction (1,2). The mechanism by which renal
toxicity develops during cadmium intoxication is
unclear, but accumulating evidence suggests that
cadmium-metallothionein (CdMT) might play a
role. Recent data suggest that Cd is transported
directly to renal proximal tubule cells in the form
of CdMT (3,4) and studies with injected CdMT
have shown that this small cadmium-containing
protein induces a renal damage similar to ionic
Cd by specifically affecting proximal tubule cells
(5-7). On a Cd basis, the LD50 ofCdMT is about 7
times that of CdCl2 (8), due most likely to its
preferential accumulation in the kidney (5,6,9).
Investigations are in progress to determine the
mechanism ofCdMT toxicity. In this regard there
are currently two mechanisms under consider-
ation. One proposes that CdMT damages the
proximal tubule cell membrane in the process of
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its reabsorption from the tubular lumen (6,10).
The second suggests that the toxic species is the
Cd2+ released from the protein moiety following
degradation of the protein within the proximal
tubule cell (8,11,12). Inthispaperthe metabolism
and toxicity ofCdMT are reviewed, and evidence
is presented to support the hypothesis that CdMT
toxicity is mediated via release of toxic levels of
Cd2+ within the cell.
Renal Metabolism of Circulating
CdMT
Circulating CdMT passesthrough the glomeru-
lus and is reabsorbed by renal proximal tubule
cells (13). Studies using 109Cd and 3H- or 35S-
labeled CdMT have shown that the protein is
rapidly degraded by lysosomes and the Cd is
released into the cell cytoplasm (5,8,12). Cain and
Holt (12) reported that an intravenous dose of3H-
CdMT is already partially degraded within 30
min ofinjection and degradation ofthe protein is
virtually complete by 4 hr. Cytoplasmic Cd is
eventually bound to newly synthesized renal me-
tallothionein; however, atearly timeperiods after
injection, a significant amount of Cd is non-thio-SQUIBB AND FOWLER
_ 0.3 mg Cd/kg), however, urine volume was increased
within 8 hr ofinjection and remained elevated for
5 days (Squibb et al., unpublished data). The
-0.2 difference in these responses is probably due to
the different degree of renal failure and tubular
blockage induced by the CdMT dose.
In addition to polyuria, a 0.6 mg Cd/kg dose of
l°0.1 ~ CdMT in rats induces low molecular weight pro-
< teinuria as evidencedbyincreasedRNAase excre-
CL tion (Fig. 2) and SDS gel electrophoretic analysis
0 of urinary proteins (Squibb et al., unpublished
data). Nordberg (16) has also reported the pres-
ence of tubular proteinuria in CdMT-treated
0.3 mice. 0-3 Ultrastructural studies have shown that in-
jected CdMT selectively affects renal proximal
tubule cells. Glomeruli and distal tubules appear
_0.2 normal while proximal tubule cells are vacuol-
ized and show signs ofcell degeneration and des-
quamation into the tubular lumen over a 24 to 48
-0.1 hr period (5-7). Morphometric analysis of early
ultrastructural changes has shown that the num-
ber of small lysosomes in proximal tubule cells
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FIGURE 1. Sephadex G-75 chromatography of renal cytosol
fractions from rats injected with CdMT (0.6 mg Cd/kg) 1 or
8 hr prior to sacrifice. Cd eluting with the void volume
fraction is referred to as high molecular weight (HMW)
protein-bound Cd. Approximately 70% ofthe Cd inthe 8 hr
sample is present as CdMT.
nein-bound (5,11,14,15). This is illustrated by the
data shown in Figure 1, in which Cd is bound
mainly to high molecular weight proteins at 1 hr
after injection of a 0.6 mg Cd/kg dose of CdMT,
however, by 8 hr approximately 70% of the cyto-
plasmic Cd is MT-bound. This suggests that the
rate at which Cd is initially released into the cell
is greater than the rate of new metallothionein
synthesis by the kidney cells. This is consistent
with data of Cain and Holt (12), indicating that
MT synthesis is not initiated until between 2 and
4 hr after injection ofCdMT.
Renal Toxicity of Circulating
CdMT
Functional alterations inducedby CdMT are, in
part, dose-dependent. Nordberg and co-workers
(7) have reported oliguria in mice 2-3 days after
injection with CdMT at a dose of 1.5 mg Cd/kg.
This dose resulted in 40% fatalities in 4 days. In
rats injected with a nonlethal dose of CdMT (0.6
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FIGURE 2. Effect of Zn pretreatment on the renal toxicity of
CdMT. Rats were injected with 20 mg Zn/kg as ZnSO4 (IP)
16 hr prior to injection with 0.6 mg Cd/kg as CdMT (IP).
Controls were injected with saline. Urine was collected
from the time ofCdMT injection to the time ofsacrifice (8
hr). Creatinine and RNAase activity were measured ac-
cording to the procedures of Fabiny and Ertingshausen
(24) and Imrie and Hutchison (25), respectively.
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FIGURE 3. Electron micrograph ofrenal proximal tubule cells ofa ratinjected with 0.6 mgCd/kg as CdMT 4 hr prior to sacrifice.
Many ofthe cells contain an increased number ofsmall apical vesicles and small lysosomes.
increases significantly within 1 hrofinjection ofa
0.6 mg Cd/kg dose ofCdMT and almost triples by
4 hr. In addition, the number ofsmall vesicles is
increased dramatically at 4 and 8 hr (11). These
changes are illustrated in the electron micro-
graph inFigure 3. At4hrafterinjection ofCdMT,
increased numbers of small vesicles and lyso-
somes are apparent in the apical portion ofmany
renal proximal tubule cells. The mechanism by
which CdMTproduces these earlyultrastructural
alterations has not been clearly identified; how-
ever, evidence from our laboratory suggests that
they might develop as a result ofan inhibition of
primarylysosomeformation anddecreasedfusion
of lysosomes with pinocytotic vesicles (Squibb et
al., unpublished data). A similar cellular vesicu-
lation occurs in maleate nephrotoxicity, in which
transport of protein from endocytic vesicles to
lysosomes is inhibited (17). Also, Mego and Cain
(18) and Lillevold (19) have reported that Cd2+
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inhibits secondary lysosome formation in liver
cells. Such an effect on the proximal tubule cell
protein reabsorption and degradation system is
consistent with the observation that CdMT in-
duces low molecular weight proteinuria.
Biochemical alterations that occur in the kid-
ney as an early result ofCdMT treatment include
nuclear and lysosomal reactions. RNA synthesis
is decreased dramatically (89%) at 4 hr after
injection (11), while lysosomal cathepsin D and
acid phosphatase activity are inhibited 50% and
31%, respectively (20). Protein synthesis and
mitochondrial respiration, on the other hand, are
not altered after 4 hr (11).
Evidence for the Involvement of
Cd2+ in CdMT Nephrotoxicity
Several lines of investigation suggest that the
nephrotoxicity of CdMT is brought about by the
release ofCd2+ within the cell following degrada-
tion of the protein moiety. In the chronic Cd
exposure situation, when Cd feeds slowly into the
kidney, toxicity does not occur until the renal
metallothionein detoxification system (21) is sat-
urated. In experimental situations inwhich acute
doses ofCdMT are injected, toxicity is exerted at
much lower renal levels ofCd because the rate at
which Cd is released into the cell exceeds the
immediate capacity of the renal metallothionein
system (8,11,12).
In support ofthis proposed mechanism, studies
by Cain and Holt (12) have shown that soluble Cd
is non-thionein-bound and therefore potentially
toxic as early as 30 min after an intravenous
injection of CdMT. By 4 hr, almost 70% of the
renal burden of Cd is non-thionein-bound and,
although new thionein synthesis is initiated be-
tween 2 and4 hr afterinjection, even at 7 hrthere
is still a significant amount of non-thionein-
bound Cd in the cells. It was not until 24 hr that
most ofthe cellular Cd was recovered in the MT-
bound form. These findings are consistent with
data presented in Figure 1 which show that there
is still a considerable amount of non-thionein-
bound Cd present 8 hr after injection of a toxic
(0.6 mg Cd/kg) dose ofCdMT. These data indicate
that there is a time span of at least 8 hr during
whichpotentiallytoxic Cd ispresent inrenal cells
following injection ofCdMT.
Many ofthe alterations inducedby CdMT occur
within the first 8 hr after injection, in keeping
with the time interval during which Cd remains
bound to non-thionein components. Functional
alterations in urine volume control and protein
reabsorption are detectable by 8 hr (Fig. 2). 'the
number of small lysosomes is increased as early
as 1 hr after injection and the number ofvesicles
is increased by 4 hr (11). Lysosomal cathepsin D
and acid phosphatase activities are also inhibited
by4hr(20). The effectofCdMTonRNAsynthesis
also appears to be directly related to the level of
non-thionein-bound Cd in the cell (11). Inhibition
of RNA synthesis is greatest at 4 hr after injec-
tion but is diminished by 8 hr when the level of
non-thionein-bound Cd is lower due to renal me-
tallothionein synthesis. Hidalgo and co-workers
(22,23) have shown a similar effect ofCd on RNA
polymerase activity in the liver. These authors
demonstrated that the inhibition was inversely
related to Cd binding to cellular metallothionein.
The fact that the presence ofelevated levels of
metallothionein in kidneys protects against
CdMT toxicity also suggests that liberated Cd
ions are the primary cause ofCdMT toxicity. This
was first reported by Webb and Etienne (8) in
studies in which ZnMT pretreatment protected
rats againstlethal dosesofCdMT. Ithas4lsobeen
observed that functional alterations induced by
CdMT are prevented by Zn pretreatment. As
shown in Figure 2, effects ofCdMT treatment on
urine volume, creatinine and RNAase excretion
were not observed in animals in which renal MT
levels were elevated approximately 4-fold by Zn
treatment. In these same animals, Zn pretreat-
ment increased the binding of Cd to MT and
decreased the non-thionein-bound Cd (Fig. 4). At
8 hr after CdMT treatment, the amount of Cd
bound to the high molecular weight (HMW) pro-
teins ofkidney cytosol, as measured by Sephadex
G75 chromatography, was decreased from 15.5%
HMW Protein-Bound Cd
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FIGURE 4. Effect ofZn pretreatment on the binding ofCd to
high molecular weight (HMW) proteins 8 hr after CdMT
(0.6 mg Cd/kg) treatment. HMW protein-bound Cd is the
Cd present in the void volume fractions following Sepha-
dex G-75 chromatography of kidney cytosol (see Fig. 1).
Bars represent SDs; n = 3.
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of the cytosolic Cd to 4.2% by Zn pretreatment.
These data suggest that the elevated MT levels
decrease the toxicity of CdMT by decreasing the
non-thionein-bound pool of Cd and thus provide
further evidence that Cd2+ released from injected
CdMT is responsible for many ofthe toxic effects
ofCdMT.
In summary, the renal toxicity ofCdMT is due
to its rapid uptake and degradation by renal
proximal tubule cells. Effects on lysosomal en-
zyme activities, RNA synthesis and possibly
membrane fusion processes appear to be due to
the rapid release of toxic Cd2+ ions within the
cells.
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